CDX2 is a useful marker of intestinal-type differentiation: a tissue microarray-based study of 629 tumors from various sites.
CDX2 is a useful marker of intestinal-type differentiation: a tissue microarray-based study of 629 tumors from various sites.
复制标题
CDX2 是肠型分化的有用标记：对来自不同部位的 629 个肿瘤进行的基于组织微阵列的研究。
DOI：
--
复制
发表时间：
2005
影响因子：
4.6
通讯作者：
W. Frankel
中科院分区：
文献类型：
--
作者：
Lindsey B De Lott;C. Morrison;S. Suster;D. Cohn;W. Frankel
上下文
CDX 2是肠发育的关键核转录因子，在肠上皮和腺癌中表达。
目标
确定CDX 2是否是结肠癌分化的有用标志物，并将肿瘤组织学与结直肠腺癌中的CDX 2染色相关联。
设计
来自71个结直肠腺癌、31个肝细胞癌、47个肺腺癌、55个肺鳞状细胞癌、69个肺神经内分泌癌和43个胰腺神经内分泌癌、57个胰腺腺癌和256个子宫内膜腺癌的组织微阵列用抗CDX 2抗体染色。
结果
71例结直肠癌中51例（71.8%）CDX 2染色阳性，其中高、中分化癌38例（74.5%），高分化癌13例（65.0%）。在高级别肿瘤中，7例粘液性肿瘤中5例（71.4%）阳性，3例印戒细胞性肿瘤中3例（100%）阳性，10例低分化肿瘤中5例（50.0%）阳性。其他显示偶见CDX 2染色的肿瘤包括1/30的肺高分化或中分化神经内分泌癌和2/43的胰腺癌、1/47的肺腺癌、3/57的胰腺腺癌和15/256的子宫内膜癌。肝细胞、肺低分化神经内分泌癌和肺鳞状细胞癌对CDX 2无免疫反应性。
结论
CDX 2是一种有用的肿瘤型分化的标志物，在其他评估部位的肿瘤中很少见到，并且可能有助于确定某些转移性肿瘤的起源部位。然而，CDX 2不是低分化结直肠癌的敏感标志物。
CONTEXT
CDX2, a critical nuclear transcription factor for intestinal development, is expressed in intestinal epithelium and adenocarcinomas.
OBJECTIVES
To determine if CDX2 is a useful marker for intestinal-type differentiation and to correlate tumor histology with CDX2 staining in colorectal adenocarcinomas.
DESIGN
Tissue microarrays from 71 colorectal adenocarcinomas, 31 hepatocellular carcinomas, 47 lung adenocarcinomas, 55 squamous cell carcinomas of the lung, 69 neuroendocrine carcinomas of the lung and 43 of the pancreas, 57 pancreatic adenocarcinomas, and 256 endometrial adenocarcinomas were stained with antibody against CDX2.
RESULTS
CDX2 staining was positive in 51 (71.8%) of 71 colorectal cancers, including 38 (74.5%) of 51 well- or moderately differentiated tumors and 13 (65.0%) of 20 high-grade tumors. Of the high-grade tumors, 5 (71.4%) of 7 mucinous, 3 (100%) of 3 signet ring cell, and 5 (50.0%) of 10 poorly differentiated tumors were positive. Other tumors showing occasional CDX2 staining included 1 of 30 well- or moderately differentiated neuroendocrine carcinomas of the lung and 2 of 43 from the pancreas, 1 of 47 lung adenocarcinomas, 3 of 57 pancreatic adenocarcinomas, and 15 of 256 endometrial carcinomas. Hepatocellular, poorly differentiated neuroendocrine carcinoma of the lung and squamous cell carcinomas of the lung were not immunoreactive for CDX2.
CONCLUSIONS
CDX2 is a useful marker for intestinal-type differentiation, is rarely seen in tumors from the other sites evaluated, and may be useful in determining the site of origin for some metastatic tumors. However, CDX2 is not a sensitive marker for poorly differentiated colorectal carcinoma.
登录
查看更多内容
影响因子：
6
作者：
Hinoi, T;Tani, M;Fearon, ER
通讯作者：
Fearon, ER
影响因子：
29.4
作者：
Fang, RX;Santiago, NA;Sibley, E
通讯作者：
Sibley, E
影响因子：
29.4
作者：
Silberg, DG;Sullivan, J;Kaestner, KH
通讯作者：
Kaestner, KH
影响因子：
4.8
作者：
Boudreau, F;Rings, EHHM;Traber, PG
通讯作者：
Traber, PG
影响因子：
29.4
作者：
Silberg, DG;Swain, GP;Traber, PG
通讯作者：
Traber, PG